Axicabtagene Ciloleucel

Introduction Overview

Generic Name

axicabtagene ciloleucel

Brand Name

Yescarta

Dosage Form

suspension for intravenous infusion

Drug Class

Miscellaneous antineoplastics (CAR T-cell therapy)

Pharmacokinetics

Pharmacokinetics of axicabtagene ciloleucel (Yescarta) represent a unique profile due to the nature of CAR T-cell therapy, which involves the administration of genetically engineered autologous T-cells rather than a conventional small molecule or biologic drug.

Absorption:
Yescarta is administered via intravenous infusion directly into the bloodstream, bypassing absorption processes common to oral or other routes. Upon infusion, axicabtagene ciloleucel T-cells circulate and distribute systemically without requiring gastrointestinal absorption. The autologous T-cells subsequently expand and persist in the patient's circulation.

Distribution:
Post-infusion, the CAR T-cells distribute broadly within the peripheral blood and lymphoid tissues. They preferentially home to sites expressing the CD19 antigen, including lymphoma sites in lymph nodes, bone marrow, and other tissues. The cellular distribution is influenced by chemokine gradients, antigen presence, and T-cell trafficking mechanisms. The biodistribution underpins the therapeutic targeting of malignant B-cells expressing CD19.

Metabolism:
Axicabtagene ciloleucel is a cellular therapy; therefore, metabolism pertains to the life cycle and viability of the infused CAR T-cells rather than biochemical metabolism by hepatic or enzymatic pathways. The cells may proliferate, become activated, or undergo apoptosis. Metabolic pathways of these modified T-cells follow normal cellular metabolic processes within the host, including glucose metabolism and cytokine production.

Elimination:
Elimination of the therapy refers primarily to the loss of CAR T-cells through natural cellular turnover, immune clearance, or exhaustion. Persistence of CAR T-cells varies among patients, with long-term engraftment observed in some, contributing to durable responses and potential cures. No pharmacokinetic parameters such as half-life apply conventionally, but persistence can be monitored by quantification of CAR transgene copies in peripheral blood.

Overall, the pharmacokinetics of Yescarta differ fundamentally from traditional drugs, involving cellular expansion, trafficking, and persistence, which govern therapeutic efficacy and safety profiles.

Dosage Forms

Available Dosage Forms:
Yescarta is supplied as a frozen suspension of genetically modified autologous T-cells for intravenous infusion. Each infusion bag contains approximately 68 mL of suspension containing a target dose of 2 × 10^6 CAR-positive viable T cells per kilogram of body weight, with a maximum of 2 × 10^8 CAR-positive viable T cells per infusion. The suspension includes excipients such as 5% dimethyl sulfoxide (DMSO) and 2.5% human albumin.

Dosages for Adults and Adolescents:
The standard dosing regimen for adults with large B-cell lymphoma or follicular lymphoma involves a single one-time intravenous infusion. Prior to infusion, patients receive a three-day lymphodepleting chemotherapy regimen consisting of cyclophosphamide and fludarabine to optimize T-cell expansion. On infusion day, the target dose is 2 × 10^6 CAR-positive viable T cells per kg, capped at 2 × 10^8 total cells. Infusion is administered over approximately 30 minutes.

Specific Patient Populations:
Yescarta therapy is indicated exclusively for adult patients; pediatric or adolescent use is not approved. Dose adjustments are not typically made based on renal or hepatic function due to the nature of cell therapy. Patients with primary central nervous system lymphoma are not candidates for Yescarta. Safety and efficacy in pregnancy and breastfeeding have not been established; pregnancy testing and contraception are recommended around the treatment period. Close monitoring is advised in patients with pre-existing neurologic or cardiac conditions due to potential treatment-related toxicities.

Mechanism Of Action

Yescarta (axicabtagene ciloleucel) is a chimeric antigen receptor (CAR) T-cell therapy designed to redirect a patient's own T-cells to recognize and destroy B-cell lymphoma cells expressing the CD19 antigen. The therapy involves genetic modification of autologous T-cells to express a synthetic receptor combining an antigen-recognition domain with intracellular T-cell activation motifs.

The primary molecular mechanism entails the fusion of a single-chain variable fragment (scFv) antibody domain targeting CD19 with T-cell signaling domains, including CD3-zeta and costimulatory domains (such as CD28). This receptor enables the engineered T-cells to identify and bind CD19 molecules on malignant B-cells independently of major histocompatibility complex (MHC) restriction, a key escape mechanism of cancer cells.

Upon binding to CD19-positive tumor cells, activation cascades trigger proliferation, cytokine secretion, and cytotoxic responses of the CAR T-cells. These immune effector functions include the release of perforin and granzymes, leading to targeted apoptosis of B-cells. The modified T-cells can expand in vivo, sustaining anti-tumor activity and promoting durable remission.

Clinically, this approach allows precise targeting of B-cell malignancies refractory to conventional therapies, with evidence from pivotal trials demonstrating substantial response rates. Compared to other treatments, such as monoclonal antibodies or chemotherapies, CAR T-cell therapy uniquely harnesses and amplifies cellular immunity with long-lasting immunologic memory, offering potential curative outcomes in previously incurable lymphomas.

Pharmacological Actions

Genetically engineered autologous T-cell immunotherapy targeting CD19 antigen on B-cells.
Activation and expansion of CAR T-cells upon recognition of CD19-expressing lymphoma cells.
Induction of tumor cell apoptosis via cytotoxic granule release and immune-mediated killing.
Bypassing traditional MHC restriction to overcome tumor immune evasion.
Sustained immune surveillance through long-term persistence of CAR T-cells in circulation.
Modulation of the tumor microenvironment by cytokine release and T-cell infiltration.
Capability of single-dose administration providing durable remission in refractory lymphoma.
Lymphodepleting chemotherapy sensitization enhancing CAR T-cell expansion and effectiveness.
Potential for immune memory formation reducing relapse rates.
High specificity limiting off-target cytotoxicity primarily to CD19-expressing B cells.
Immunomodulatory effects including cytokine release syndrome (CRS) related to rapid T-cell activation.
Interaction with host immune cells influencing therapeutic response and toxicity.
Potential to cause B-cell aplasia due to targeting of normal CD19-positive B cells.
Immunogenicity considerations related to transgene expression and patient immune status.

Therapeutic Or Clinical Uses

Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified.
Management of primary mediastinal large B-cell lymphoma in adults with relapsed or refractory disease.
Therapy for high-grade B-cell lymphoma refractory to standard chemoimmunotherapy.
Treatment of relapsed or refractory follicular lymphoma (FL) after two or more prior systemic therapies.
One-time infusion as a personalized therapy that provides durable remission in aggressive B-cell lymphomas.
Salvage therapy for patients ineligible for or who have failed autologous stem cell transplantation.
Approved for adult patients with large B-cell lymphoma refractory or relapsed within 12 months of first-line chemoimmunotherapy.
Use in patients with lymphoma subtypes arising from transformation of follicular lymphoma.
Treatment option in cases where conventional chemotherapies have failed or are contraindicated.
Car T-cell therapy as an adjunct to lymphodepleting chemotherapy regimen prior to infusion.
Therapeutic option offering improved event-free and overall survival compared to standard transplant in select populations.
Use restricted to centers certified to administer and monitor CAR T-cell therapies due to toxicity risks.
Not indicated for primary central nervous system lymphoma.
Emerging indications pending ongoing clinical trials and regulatory approvals.
Alternative therapy in patients with limited treatment options and poor prognosis.

Side Or Adverse Effects

Fever (≥100.4°F/38°C), often associated with cytokine release syndrome.
Neutropenia and other forms of cytopenias (low white and red blood cells).
Hypotension causing dizziness, lightheadedness, fatigue, and shortness of breath.
Tachycardia or fast heartbeat following infusion.
Neurologic toxicities including confusion, impaired speech, seizures, and encephalopathy.
Nausea and diarrhea as gastrointestinal adverse effects.
Cytokine release syndrome (CRS), a potentially life-threatening hyperinflammatory state.
Secondary blood cancers due to transformation of genetically modified T-cells.
Hypersensitivity reactions during infusion, possibly related to DMSO or residual antibiotics, including anaphylaxis.
Serious infections due to immunosuppression and B-cell aplasia.
Prolonged cytopenias lasting several weeks post-infusion.
Hypogammaglobulinemia resulting from B-cell depletion.
Potential severe fatigue and weakness impairing functional status.
Neurologic adverse events such as tremor, delirium, speech difficulty, dizziness, and insomnia.
Risk of organ dysfunction related to severe systemic inflammatory responses.

Precautions

Monitor for early signs of cytokine release syndrome and neurologic toxicities immediately following infusion.
Avoid live vaccines within six weeks prior to lymphodepleting chemotherapy and until immune recovery after therapy.
Assess patients carefully for pre-existing neurologic, cardiac, hepatic, and pulmonary conditions prior to treatment.
Pregnancy testing recommended in women of childbearing potential with contraception advised during and after therapy.
Avoid driving and operating machinery for at least two weeks after infusion due to neurologic adverse effects.
Inform all healthcare providers of Yescarta treatment history to guide care and monitor side effects.
Maintain proximity to a certified healthcare facility for at least four weeks post-infusion for close monitoring.
Vaccination with live virus vaccines contraindicated from six weeks before chemotherapy until immune reconstitution.
Regular blood tests needed to monitor cytopenias, immunoglobulin levels, and treatment response.
Be vigilant for infusion-related hypersensitivity reactions and manage promptly.
Counsel patients on avoiding blood, organ, tissue, or cell donation after therapy.
Immunoglobulin replacement therapy may be necessary for hypogammaglobulinemia.
Evaluate and manage infections aggressively due to immunosuppression.
Educate patients about symptoms requiring immediate medical attention such as severe fever, confusion, or respiratory distress.
Careful consideration in patients with active infections to reduce complications.

Warnings

Boxed warning for cytokine release syndrome (CRS), a severe and potentially fatal systemic inflammatory response.
Boxed warning for neurologic toxicities including encephalopathy, seizures, confusion, and speech difficulties which may be life-threatening.
Risk of secondary blood cancers arising from malignant transformation of the infused CAR T-cells.
Potential for life-threatening hypersensitivity or anaphylactic reactions during infusion.
Use in centers certified and experienced in CAR T-cell therapy administration and management of associated toxicities.
Delayed onset of severe side effects necessitating prolonged monitoring post-infusion.
Potential for prolonged cytopenias increasing risk of serious infections and bleeding events.
Avoid use in patients with primary central nervous system lymphoma due to lack of safety and efficacy data.
Not recommended for use with systemic corticosteroids or other immunosuppressants that may reduce CAR T-cell efficacy.
Pregnancy category unknown; treatment may harm fetus through unknown mechanisms.
Risk of severe hypogammaglobulinemia requiring immunoglobulin replacement.
Potential exacerbation of pre-existing neurologic or cardiovascular diseases post-therapy.
Must have immediate access to tocilizumab and emergency supportive care for CRS management.
Infections including severe bacterial, viral, and fungal are common and pose substantial morbidity.
Patients should carry a Yescarta Patient Wallet Card documenting treatment history for emergency care.

Contraindication

Known hypersensitivity to axicabtagene ciloleucel or any component of the formulation including albumin or dimethyl sulfoxide (DMSO).
Patients with primary central nervous system (CNS) lymphoma due to lack of efficacy and safety data.
Active uncontrolled infection prior to lymphodepleting chemotherapy and infusion.
Patients unable to be treated at or near a certified center capable of managing severe adverse events.
Concurrent treatment with systemic corticosteroids or other immunosuppressants that interfere with CAR T-cell activity.
Pregnant or breastfeeding women due to unknown fetal and infant risks.
Patients who have not undergone necessary pre-infusion lymphodepleting chemotherapy regimen.
Patients with severe comorbidities precluding safe administration or monitoring of therapy.
Any condition where leukapheresis is contraindicated or cannot obtain sufficient viable T-cells.
Known severe hypersensitivity reactions to components of the cell suspension or infusion-related excipients.
Patients unwilling or unable to comply with monitoring requirements including prolonged hospitalization.
Contraindicated in patients with compromised pulmonary, hepatic, or cardiac function if unable to tolerate treatment toxicities.
Use contraindicated if live virus vaccination has been administered within six weeks prior to lymphodepleting chemotherapy.
Patients with active autoimmune diseases not controlled with therapy, which may be exacerbated by immune activation.
Contraindicated in patients with prior graft-versus-host disease or allogeneic stem cell transplant without adequate assessment.

Drug Interactions

Systemic corticosteroids may suppress CAR T-cell expansion and activity, reducing therapeutic efficacy.
Immunosuppressive agents may interfere with CAR T-cell proliferation and function.
Concomitant chemotherapy agents prior to infusion as specified in lymphodepleting regimen (cyclophosphamide and fludarabine).
Live vaccines are contraindicated during treatment period due to immunosuppression.
Drugs modulating cytokine response may influence severity of cytokine release syndrome.
Concomitant use of medications causing hematologic toxicity may exacerbate cytopenias.
Agents prolonging QT interval are to be used cautiously due to potential for cardiac side effects induced by CRS.
Drugs affecting renal or hepatic function warrant careful monitoring but do not have direct interaction with Yescarta cells.
Medications that affect immune checkpoints or immune cell activation could theoretically alter CAR T-cell activity.
Infections requiring antimicrobial therapy should be carefully managed to avoid immunologic interference.
Potential interaction with anticoagulants given thrombocytopenia risks; monitor bleeding.
No known direct drug interactions with herbal supplements, but immunomodulatory effects should be considered.
Monitoring required when introducing new medications during Yescarta treatment and recovery.
Supportive care medications such as acetaminophen and antihistamines are used to mitigate infusion reactions without interactions.
Tocilizumab and corticosteroids are employed to manage CRS and neurologic events but may impact CAR T-cell persistence.

Preparations Of The Drug

Yescarta is prepared from autologous T-cells collected via leukapheresis from the patient.
The collected T-cells are sent to a specialized manufacturing facility where they are genetically modified ex vivo to express the anti-CD19 chimeric antigen receptor.
The cell product is expanded, formulated as a cryopreserved suspension in an infusion bag containing approximately 68 mL volume.
Excipient components include 5% dimethyl sulfoxide (DMSO) as a cryoprotectant and 2.5% human albumin to maintain cell viability.
Final product is stored frozen until ready for shipment back to the treatment center for infusion.
Before infusion, patients undergo lymphodepleting chemotherapy to prepare the immune environment for CAR T-cell expansion.
Premedication with acetaminophen and an H1-antihistamine is given to reduce infusion-related reactions.
The infusion process takes approximately 30 minutes and is performed through a central or peripheral intravenous catheter.
Manufacturing and preparation are individually customized per patient to ensure product specificity and safety.
The time from leukapheresis to infusion typically spans several weeks during which quality control testing is performed.
Patients must be treated at centers certified in handling and administration of CAR T-cell therapies.
Supportive care protocols include monitoring for cytokine release syndrome and neurologic toxicities immediately post-infusion.
Patients receive a Yescarta Patient Wallet Card with treatment details and emergency contact information.
No generic versions or alternative preparations are currently available; the product is proprietary.
Preparation requires adherence to stringent cellular therapy handling standards including cold chain logistics.